目的: 探讨75 岁以上老年人使用免疫检查点抑制剂的不良反应, 讨论免疫衰老以及老年癌症患者
的免疫治疗毒性以及相关毒性的管理. 方法: 收集2018 年1 月1 日—2021 年12 月31 …

Background: Immunotherapy has completely changed the treatment of solid tumors.
Although immune checkpoint inhibitors (ICIs) seem to be an appealing alternative to …

The number of older patients with cancer is increasing as a result of the ageing of Western
societies. Immune checkpoint inhibitors have improved cancer treatment and are associated …

免疫检查点抑制剂(immune checkpoint inhibitors, ICIs) 是当今肿瘤治疗领域的革命性突破,
改变了多种肿瘤治疗模式. 老年人占肿瘤现患人数及死亡人数的绝大部分 …

Objective To observe the toxicities of immune checkpoint inhibitors. Methods We
retrospectively analyzed the clinical data of 20 advanced tumor patients who received …

Purpose Older patients with cancer are underrepresented in pivotal trials of immune
checkpoint inhibitors (ICIs). This study aimed to investigate immune-related adverse events …

Introduction Increased immune checkpoint inhibitor (ICI) use in various advanced cancer
types has led to a parallel rise in immune-related adverse events (irAEs). Despite …

Methods We retrospectively analyzed the clinical data of 20 advanced tumor patients who
received immune checkpoint inhibitors therapy in Cancer Hospital of Chinese Academy of …

In the last decade, immune checkpoint inhibitors (ICIs) targeting cytotoxic T-lymphocyte-
associated protein 4 (CTLA-4), programmed cell death 1 (PD-1), and its ligand (PD-L1) …

Background Immuno-oncology (IO) drugs are essential for treating various cancer types;
however, safety concerns persist in older patients. Although the incidence of immune-related …